Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| monoclonal antibodies | 5761 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Vilobelimab is a chimeric monoclonal IgG4-kappa antibody that binds to C5a with a dissociation constant of 9.6pM and blocks its interaction with the C5a receptor. C5a is part of the complement system and is activated as part of the innate immune response initiating an inflammatory cascade that includes increased vascular permeability, coagulation, proinflammatory cytokine release, and recruitment and activation of neutrophils and other myeloid cells.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 13, 2025 | EMA | InflaRx GmbH |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AJ10 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Complement inhibitors |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D007166 | Immunosuppressive Agents |
| MeSH PA | D051056 | Complement Inactivating Agents |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| SARS-CoV2-induced acute respiratory distress syndrom | indication | 840539006 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Complement C5 | Secreted | BINDING AGENT | Kd | 9.59 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 2250440-41-4 | SECONDARY_CAS_RN |
| CHEMBL2109636 | ChEMBL_ID |
| C000706656 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11346 | IUPHAR_LIGAND_ID |
| DB16416 | DRUGBANK_ID |
| 4042164 | VANDF |
| 4042165 | VANDF |
| C5392705 | UMLSCUI |
| CHEBI:754373 | CHEBI |
| 11304 | INN_ID |
| D11838 | KEGG_DRUG |
| 137254326 | PUBCHEM_CID |
| 366270 | MMSL |
| 41391 | MMSL |
| d10030 | MMSL |
| 019374 | NDDF |
| F5T0RF9ZJA | UNII |
| 2639620 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| GOHIBIC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83000-110 | INJECTION | 10 mg | INTRAVENOUS | Emergency Use Authorization | 27 sections |